CY1121523T1 - Βελτιστοποιημενο φαρμακευτικο σκευασμα για την θεραπεια φλεγμονωδων αλλοιωσεων του οισοφαγου - Google Patents

Βελτιστοποιημενο φαρμακευτικο σκευασμα για την θεραπεια φλεγμονωδων αλλοιωσεων του οισοφαγου

Info

Publication number
CY1121523T1
CY1121523T1 CY20191100386T CY191100386T CY1121523T1 CY 1121523 T1 CY1121523 T1 CY 1121523T1 CY 20191100386 T CY20191100386 T CY 20191100386T CY 191100386 T CY191100386 T CY 191100386T CY 1121523 T1 CY1121523 T1 CY 1121523T1
Authority
CY
Cyprus
Prior art keywords
treatment
esophages
esophagus
inflammatory changes
effervescent tablet
Prior art date
Application number
CY20191100386T
Other languages
English (en)
Inventor
Roland Greinwald
Ralph Müller
Markus PRÖLS
Rudolf Wilhelm
Original Assignee
Dr. Falk Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49911300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121523(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dr. Falk Pharma Gmbh filed Critical Dr. Falk Pharma Gmbh
Publication of CY1121523T1 publication Critical patent/CY1121523T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Συνοπτικά, προσφέρεται ένα βελτιστοποιημένο φαρμακευτικό σκεύασμα για τη θεραπεία φλεγμονωδών αλλοιώσεων του οισοφάγου. Το φαρμακευτικό σκεύασμα ενός διασπειρόμενου στο στόμα αναβράζοντος δισκίου είναι σταθερό, παράγεται εύκολα και μπορεί να χρησιμοποιηθεί χωρίς να διαλυθεί σε υγρό. Δεν χρειάζεται επιπλέον πόση υγρού που θα συντόμευε τον χρόνο παραμονής του διαλύματος βουδεσονίδης στην προσβεβλημένη περιοχή του οισοφάγου. Το σύμφωνο με την εφεύρεση αναβράζον δισκίο είχε απροσδόκητα ως αποτέλεσμα μια απρόσμενα υψηλή ιστολογική ύφεση σε ασθενείς με ενεργή ηωσινοφιλική οισοφαγίτιδα.
CY20191100386T 2013-12-23 2019-04-08 Βελτιστοποιημενο φαρμακευτικο σκευασμα για την θεραπεια φλεγμονωδων αλλοιωσεων του οισοφαγου CY1121523T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13199278.6A EP2886108B2 (de) 2013-12-23 2013-12-23 Optimierte pharmazeutische Formulierung zur Behandlung von entzündlichen Veränderungen des Ösophagus

Publications (1)

Publication Number Publication Date
CY1121523T1 true CY1121523T1 (el) 2020-05-29

Family

ID=49911300

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20181101233T CY1121168T1 (el) 2013-12-23 2018-11-21 Βελτιστοποιημενο φαρμακευτικο σκευασμα για αγωγη φλεγμονωδων εξαλλαγων του οισοφαγου
CY20191100386T CY1121523T1 (el) 2013-12-23 2019-04-08 Βελτιστοποιημενο φαρμακευτικο σκευασμα για την θεραπεια φλεγμονωδων αλλοιωσεων του οισοφαγου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20181101233T CY1121168T1 (el) 2013-12-23 2018-11-21 Βελτιστοποιημενο φαρμακευτικο σκευασμα για αγωγη φλεγμονωδων εξαλλαγων του οισοφαγου

Country Status (24)

Country Link
US (4) US9867780B2 (el)
EP (2) EP2886108B2 (el)
JP (3) JP6522626B2 (el)
CN (1) CN105848648B (el)
AU (1) AU2014372739B2 (el)
CA (1) CA2934009C (el)
CY (2) CY1121168T1 (el)
DK (2) DK2886108T4 (el)
EA (1) EA029166B1 (el)
ES (2) ES2716990T5 (el)
FI (1) FI2886108T4 (el)
HK (1) HK1209362A1 (el)
HR (2) HRP20190677T4 (el)
HU (2) HUE042009T2 (el)
IL (1) IL246172B (el)
LT (2) LT2886108T (el)
PL (2) PL2886108T5 (el)
PT (2) PT2886108T (el)
RS (2) RS58543B2 (el)
SI (2) SI2886108T2 (el)
TR (1) TR201815823T4 (el)
UA (1) UA117162C2 (el)
WO (1) WO2015097053A1 (el)
ZA (1) ZA201604225B (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2742525T3 (es) 2009-10-01 2020-02-14 Adare Pharmaceuticals Us L P Composiciones de corticosteroides administradas oralmente
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
SI2886108T2 (sl) * 2013-12-23 2023-02-28 Dr. Falk Pharma Gmbh Optimizirana farmacevtska formulacija za zdravljenje vnetnih sprememb požiralnika
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
EP4091615A1 (en) 2021-05-20 2022-11-23 Dr. Falk Pharma Gmbh Orodispersible effervescent tablet comprising budesonide for use in the treatment of eosinophilic esophagitis
CN116869927B (zh) * 2023-09-06 2023-11-10 中国医学科学院北京协和医院 一种用于治疗嗜酸性食管炎的食道温敏凝胶

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3937455A1 (de) * 1989-11-10 1991-05-16 Nordmark Arzneimittel Gmbh Antacidatabletten
DK0481294T4 (da) * 1990-10-19 2001-06-18 Spirig Ag Fast, hurtigt-opløseligt lægemiddelpræparat indeholdende N-acetylcystein
DE4332394A1 (de) 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US5807577A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5807578A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
FR2834893B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible de perindopril
WO2003080023A2 (en) 2002-03-20 2003-10-02 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
EP1595533B1 (en) 2003-01-21 2010-01-06 Nippon Shinyaku Co., Ltd. Tablet quickly melting in oral cavity
SE0401031D0 (sv) 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US20060013873A1 (en) 2004-07-16 2006-01-19 Chih-Chiang Yang Bioadhesive dosage form of steroids
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20070071817A1 (en) 2005-09-26 2007-03-29 Phyzz, Inc. Effervescent oral care compositions and method of use
US8679545B2 (en) * 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CA2642577A1 (en) 2006-02-15 2007-08-23 Tika Lakemedel Ab Methods of manufacturing corticosteroid solutions
BRPI0817927A2 (pt) 2007-10-01 2015-04-07 Lesvi Laboratorios Sl Comprimidos orodispersiveis
MX349677B (es) 2007-11-13 2017-08-08 Meritage Pharma Inc Composiciones corticosteroides.
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
PL2151235T3 (pl) * 2008-07-21 2011-05-31 Dr Falk Pharma Gmbh Preparat farmaceutyczny do leczenia górnego przewodu pokarmowego
US20100034894A1 (en) 2008-08-08 2010-02-11 Szymczak Christopher E Use of Sucralose as a Granulating Agent
US20110097401A1 (en) * 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
SI2886108T2 (sl) 2013-12-23 2023-02-28 Dr. Falk Pharma Gmbh Optimizirana farmacevtska formulacija za zdravljenje vnetnih sprememb požiralnika

Also Published As

Publication number Publication date
WO2015097053A1 (de) 2015-07-02
ES2694331T3 (es) 2018-12-19
JP6757444B2 (ja) 2020-09-16
DK3086782T3 (en) 2018-11-26
US10369100B2 (en) 2019-08-06
US20200337997A1 (en) 2020-10-29
US20160324772A1 (en) 2016-11-10
TR201815823T4 (tr) 2018-11-21
PL2886108T3 (pl) 2019-08-30
HRP20190677T1 (hr) 2019-05-31
EP3086782A1 (de) 2016-11-02
ES2716990T5 (es) 2023-03-24
EP2886108A1 (de) 2015-06-24
AU2014372739B2 (en) 2019-06-13
EA201600497A1 (ru) 2017-03-31
PL3086782T3 (pl) 2019-03-29
CA2934009A1 (en) 2015-07-02
EP2886108B2 (de) 2022-11-02
JP6522626B2 (ja) 2019-05-29
HK1209362A1 (en) 2016-04-01
PT2886108T (pt) 2019-04-01
SI2886108T1 (sl) 2019-05-31
DK2886108T3 (en) 2019-04-01
SI2886108T2 (sl) 2023-02-28
CN105848648A (zh) 2016-08-10
ZA201604225B (en) 2017-08-30
US10695291B2 (en) 2020-06-30
JP2019142931A (ja) 2019-08-29
JP2017500361A (ja) 2017-01-05
ES2716990T3 (es) 2019-06-18
HRP20190677T4 (hr) 2023-02-03
US9867780B2 (en) 2018-01-16
CA2934009C (en) 2020-03-10
EA029166B1 (ru) 2018-02-28
LT2886108T (lt) 2019-03-25
JP2020196753A (ja) 2020-12-10
US20180185277A1 (en) 2018-07-05
CN105848648B (zh) 2019-08-06
SI3086782T1 (sl) 2018-11-30
FI2886108T4 (fi) 2023-02-22
US11382860B2 (en) 2022-07-12
AU2014372739A1 (en) 2016-07-07
RS58543B1 (sr) 2019-04-30
PT3086782T (pt) 2018-11-19
EP3086782B1 (de) 2018-09-26
HRP20181799T1 (hr) 2018-12-28
PL2886108T5 (pl) 2023-02-27
HUE041911T2 (hu) 2019-06-28
EP2886108B1 (de) 2019-02-06
IL246172B (en) 2019-01-31
DK2886108T4 (da) 2023-01-30
NZ721495A (en) 2020-12-18
JP7009575B2 (ja) 2022-01-25
RS58543B2 (sr) 2023-02-28
CY1121168T1 (el) 2020-05-29
US20190358155A1 (en) 2019-11-28
UA117162C2 (uk) 2018-06-25
RS58112B1 (sr) 2019-02-28
HUE042009T2 (hu) 2019-06-28
IL246172A0 (en) 2016-07-31
LT3086782T (lt) 2018-11-26

Similar Documents

Publication Publication Date Title
CY1121523T1 (el) Βελτιστοποιημενο φαρμακευτικο σκευασμα για την θεραπεια φλεγμονωδων αλλοιωσεων του οισοφαγου
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
BR112018010671A8 (pt) dispositivos e métodos de distribuição de fármaco com mudança de forma
DK3068393T5 (da) Kombinationsterapi som inkluderer en mdm2-inhibitor og et eller flere yderligere farmaceutisk aktive midler til behandlingen af kræftformer
CY1122113T1 (el) Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου
CL2016000143A1 (es) Comprimido farmacéutico que comprende ácido acetilsalicílico y clopidogrel
EP4233902A3 (en) Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
UY36595A (es) Formulación compleja farmacéutica que comprende amlodipina, losartán y clortalidona
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2012003209A1 (es) Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico.
CL2017002229A1 (es) Inhibidores de bace1.
Kinosian Twenty-first century home-centered medicine: it's about the touch, not the tech…
McDaniel et al. Exemplars of complex assessment and care for hospitalized older adults: Genital herpes infection
ES2560902A2 (es) Método para la determinación de la intensidad de la modificación de la potencia de un medicamento
UA114828C2 (uk) Застосування декаметоксину як фармацевтично активної речовини для лікування шлунково-кишкових та кишкових інфекцій перорально
UA111998U (uk) Застосування декаметоксину як фармацевтично активної речовини для лікування захворювань шлунково-кишкового тракту та кишкових інфекцій перорально
Wu et al. Re: Ulcickas Yood M, Oliveria SA, Cziraky M, et al. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin 2012, 28 (2): 213-19
UA114688U (uk) Спосіб лікування апендикулярної коліки у дорослих
UA103366U (en) Application of decamethoxinum as pharmaceutically active substances for the treatment of gastro-intestinal tract and intestinal infections orally.
UA103367U (en) Application of decamethoxinum as pharmaceutically active substances for the treatment of gastro-intestinal tract and intestinal infections orally.
Julia PLACES AND TRACES OF PERSONALITY